Shares of Celcuity Inc. (NASDAQ:CELC - Get Free Report) have received an average recommendation of "Buy" from the seven analysts that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $30.17.
Several research firms have recently weighed in on CELC. HC Wainwright reaffirmed a "buy" rating and set a $27.00 price target on shares of Celcuity in a research note on Friday, November 15th. Needham & Company LLC lifted their price target on shares of Celcuity from $23.00 to $29.00 and gave the company a "buy" rating in a research note on Thursday, February 6th.
Check Out Our Latest Analysis on Celcuity
Celcuity Trading Up 1.9 %
Shares of NASDAQ:CELC traded up $0.23 during trading hours on Friday, hitting $12.10. 198,357 shares of the company's stock traded hands, compared to its average volume of 238,602. Celcuity has a 1 year low of $10.35 and a 1 year high of $22.19. The business has a fifty day moving average price of $12.28 and a 200-day moving average price of $14.29. The firm has a market capitalization of $449.27 million, a P/E ratio of -4.64 and a beta of 0.73. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36.
Hedge Funds Weigh In On Celcuity
A number of large investors have recently made changes to their positions in CELC. nVerses Capital LLC acquired a new position in shares of Celcuity during the third quarter worth $33,000. Prospera Private Wealth LLC acquired a new position in shares of Celcuity during the third quarter worth $35,000. Values First Advisors Inc. acquired a new position in shares of Celcuity during the third quarter worth $86,000. SG Americas Securities LLC acquired a new position in shares of Celcuity during the third quarter worth $119,000. Finally, Bleakley Financial Group LLC acquired a new position in shares of Celcuity during the fourth quarter worth $146,000. 63.33% of the stock is owned by institutional investors and hedge funds.
Celcuity Company Profile
(
Get Free ReportCelcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Further Reading
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
